Biogen Q2 2026 revenue rose 3% to $2.74 billion, while GAAP net income attributable to shareholders fell 85% to $97 million.
GAAP diluted EPS dropped 85% to $0.66; non-GAAP diluted EPS slid 34% to $3.60.
Growth Portfolio revenue climbed 24% to $1.06 billion, topping the Legacy MS Portfolio, which fell 14% to $767 million.
GAAP cost of sales increased 28% to $777 million; GAAP core OpEx rose 26% to $1.24 billion.
Apellis integration remained on track, with the transaction expected to be accretive to non-GAAP diluted EPS in 2027 and at least $250 million run-rate synergies by end-2027.
BIIB•
